News Archive

Two DCRI fellows, one former and one current, recently contributed to a paper published in Journal of the American Medical Informatics Association on the role telehealth has played in U.S. health care during the COVID-19 pandemic. The paper, for which DCRI cardiology fellow Jedrek Wosik, MD, is the corresponding author, details how telehealth has transformed both within the Duke Health system and beyond through the collaboration of people, processes, and technology. The paper focuses on three distinct phases of the crisis caused by the novel coronavirus: outpatient care during the stay-at-home orders, the initial COVID-19 hospital surge, and recovery post-pandemic.

The study team used pediatric patients’ electronic health records to identify patients eligible for the study.

The registry, which has enrolled 1,002 patients with idiopathic pulmonary fibrosis, shares critical knowledge and insights to help combat lung disease.

Data provided to the FDA by the research network has helped to provide a fuller picture for prescribing these medications to pediatric populations.

A pragmatic comparative effectiveness study comparing Micra leadless pacemakers to conventional transvenous pacemakers found that for patients who received the novel leadless pacemakers, complicati

Oral anticoagulation (OAC), a treatment strategy commonly used to prevent stroke in patients with atrial fibrillation, may be harmful for patients with atrial fibrillation and end-stage renal disease, according to a recent study led by the DCRI. The study, which was led by the DCRI’s Sean Pokorney, MD, MBA, and published in Journal of the American College of Cardiology, used Medicare claims data to analyze a cohort of over 8,000 patients with both atrial fibrillation and end-stage renal disease.

A study led by DCRI and Duke researchers was the first to comprehensively explore skin tone as a potential factor affecting accuracy of heart rate measurements from wearable devices.

When compared to patients with non-advanced heart failure, patients with advanced heart failure had a more than three-fold higher risk of dying within a year after receiving a defibrillator.

The DCRI’s Manesh Patel, MD, who was a member of the steering committee for this late-breaking clinical trial, has been working for years to determine the best treatment strategies for patients with peripheral artery disease.

Recent evidence suggests that a novel oral anticoagulant plus a P2Y12 inhibitor may be the best treatment pathway for patients with atrial fibrillation undergoing percutaneous coronary intervention. DCRI faculty contributed to a meta-analysis recently published in JAMA Cardiology, which drew data from five clinical trials, including DCRI-led AUGUSTUS, to evaluate the safety and efficacy of four different antithrombotic regimens.